Mark M. Zalupski

Integrative clinical genomics of metastatic cancer

Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro et al. · Nature · 2017 · 904 citations · Full text

Tumor Heterogeneity, Medicine, Integrative Clinical Genomics +5

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

Yi-Mi Wu, Fengyun Su, Shanker Kalyana‐Sundaram et al. · Cancer Discovery · 2013 · 702 citations · Full text

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 467 citations

Nanotherapeutics, Pathology, Phase Ii Study +17

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Edgar Ben‐Josef, Katherine A. Guthrie, Anthony B. El-Khoueiry et al. · Journal of Clinical Oncology · 2015 · 395 citations · Full text

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation

Eileen M. O’Reilly, Jonathan W. Lee, Mark M. Zalupski et al. · Journal of Clinical Oncology · 2020 · 383 citations · Full text